Medical/Pharmaceuticals

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hema...

2024-11-28 13:04 3048

Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-11-28 12:07 4133

Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab

HONG KONG, Nov. 27, 2024 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs—cadonilimab Injection (PD-1/CTLA-4 bispecific antibody) and ivonescimab Injection (PD-1/VEGF bi...

2024-11-28 11:58 2564

Newbase Launches 'Medicrew', a VR Medical Training Platform to Accelerate Global Market Expansion

Participation in IMSH 2025 to Showcase Innovations in Medical Education SEOUL, South Korea, Nov. 28, 2024 /PRNewswire/ -- Newbase , a leader in metaverse-based medical education platforms, announced on the 28th the launch of its new product, 'Medicrew', a platform des...

2024-11-28 09:00 2518

Lunit Inks Partnership with Salud Digna to Advance AI in Medical Imaging

* AI-powered chest X-ray and mammography analysis solutions to be deployed across one ofMexico's largest healthcare networks SEOUL, South Korea, Nov. 27, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announc...

2024-11-27 22:00 2596

Prenetics Announces Third Quarter 2024 Financial Results

Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 /P...

2024-11-27 21:30 3770

Award-Winning CMUH (Taiwan) Excels at HIMSS, Leading Taiwan's Smart Healthcare Transformation

TAICHUNG, Nov. 27, 2024 /PRNewswire/ -- In HIMSS24 APAC Seoul, Healthcare Conference & Exhibition, China Medical University Hospital (CMUH) established international presence with four notable gradings: achieving the top score in the 2023 HIMSS Global Digital Health Indicator (DHI) and receiving ...

2024-11-27 21:00 2377

Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical Study in Primary Membranous Nephropathy

SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will hold investor calls on t...

2024-11-27 19:08 3592

Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC

CHENGDU, China, Nov. 27, 2024 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization inChina from National Medical Products Administration (NMPA) for the first domestically developed trophoblast cell-surface an...

2024-11-27 14:34 2711

111, Inc. Announces Third Quarter 2024 Unaudited Financial Results

* Maintained Operational Profitability for the Third Consecutive Quarter * Operating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoY * Held Positive Operating Cash Flow for Three Consecutive Quarters SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company...

2024-11-27 14:00 2385

8 in 10 say a healthier diet is important to support mental and physical health - Herbalife Asia Pacific survey

HONG KONG, Nov. 27, 2024 /PRNewswire/ -- Herbalife, a premier health and wellness company and community, today released findings from itsAsia Pacific "New Year, New Me" survey,which revealed that 85% of consumers say a healthier diet is important to support their mental and physical health. Almos...

2024-11-27 11:00 2438

VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation

GUANGZHOU, China, Nov. 26, 2024 /PRNewswire/ -- VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement. The collaboration ...

2024-11-26 22:00 2531

IMG Releases 2024 Holiday Travel Trends

* IMG has reviewed a sample of member data including more than 17,000 travel itineraries of travelers with upcoming travel plans between Thanksgiving Day and New Year's Day to determine emerging travel trends this holiday season. INDIANAPOLIS, Nov. 26, 2024 /PRNewswire/ -- IMG (International Me...

2024-11-26 22:00 1949

QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology

SINGAPORE, Nov. 26, 2024 /PRNewswire/ -- QDX proudly announces that the team led by its co-founder, Associate ProfessorGiuseppe Barca, has been honoured with the 2024 ACM Gordon Bell Prize, often referred to as the "Nobel Prize of high-performance computing." This accolade recognizes their ground...

2024-11-26 18:49 9237

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU® (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

* Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC. * Updated results of elacestrant in combination with abemaciclib show favorable efficacy regardless of theESR1 mutation status, with a manageable and predictable safet...

2024-11-26 17:16 2934

Hong Kong: A Hub of Innovation Leading the Future of AI in Healthcare,The 2nd CREATE Symposium Hosted by CAIR Concludes Successfully

HONG KONG, Nov. 26, 2024 /PRNewswire/ -- In recent years, the integration of artificial intelligence (AI) and robotics into the medical field has revolutionized healthcare technologies. The focus now is on bridging the gap between cutting-edge technologies and clinical applications to enhance di...

2024-11-26 12:08 3048

Philips releases new data revealing that APAC is leading in sustainable healthcare and innovations being showcased at RSNA that will help reduce environmental impact

* 99% of healthcare leaders in APAC say reducing the environmental impact and CO2 emissions of the industry should be top priorities for healthcare organizations, higher than global (86%) * Healthcare leaders in APAC are driving change through a range of strategies, such as using virtual care...

2024-11-26 10:00 2712

GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment

YONGIN, South Korea, Nov. 25, 2024 /PRNewswire/ -- GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with 'GC1130A', an innovative new drug for Sanfillippo syndrome type A (MPS IIIA). GC Biopharma and Novel Pharma have...

2024-11-26 08:44 2298

Duality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement

Adcendo ApS exercises its option to utilize Duality Biologics' platform to further enhance its first-in-class ADC pipeline PRINCETON, N.J., SHANGHAI and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Duality Biologics ("Duality"), a clinical-stage biotech company focusing on the discovery and deve...

2024-11-26 08:30 2180

ReviR Therapeutics and Kennedy's Disease Association Partner to Advance Treatment for Rare Neuromuscular Disorder

BRISBANE, Calif., Nov. 25, 2024 /PRNewswire/ -- ReviR Therapeutics, a pioneering biotechnology company focused on developing novel small molecule RNA modulators for neurogenetic diseases, announced a groundbreaking research grant from the Kennedy's Disease Association (KDA) to advance a therapy f...

2024-11-26 01:00 1883
1 ... 147148149150151152153 ... 646

Week's Top Stories